26 March 2020
DBL Pharmaceutical Inc. an American concern of Bangladeshi DBL Group, has achieved notable success in the generic drug market of the United States. In the last quarter, the company was named as the second largest seller of muscle relaxant “Methocarbamol” tablets, according to a recent report by IQVIA – an American health and clinical research company. The market report says, among the 13 generic drug companies selling Methocarbamol in the US, DBL Pharma holds 14.20 percent of the market share.
Methocarbamol is a widely used medicine to treat muscle pain in the US. After the expiration of the proprietary patent of the first marketer of this medicine, mostly Indian generic medicine companies started occupying the market share. By the end of 2018, DBL Group of Bangladesh got approval of the US Food and Drug Administration (FDA) to market this medicine in the United States.
In the first quarter of 2019, DBL Pharma Inc. the concern of DBL group started marketing in America after purchasing the propriety of two generic medicines of the FDA-approved Methocarbamol through contract manufacturing. DBL started with a surprise, as the third Bangladeshi initiative in the US medicine market.
DBL Pharma is hopeful of exporting medicines to other developed countries in future as well to carry forward the thrive for exploring new opportunities.